The company combines the best of both worlds – a fast-growing, cash-generating CRO business serving top pharma companies and a high-risk, high-reward drug discovery pipeline. A landmark partnership with AbbVie, which includes upfront payments of USD 350m for its obesity drug, GUBamy, highlights its innovation potential. With advanced AI platforms and new candidates like UCN2 in the pipeline, Gubra is positioned at the frontier of biotech. Watch the video to understand what the market is pricing in – and what could unlock further development? 

Gubra (One-pager): From Biotech to Techbio

Gubra – Peer News from Zealand Pharma

Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos

Meet and ask questions to Gubra’s management – CEO Henrik Blou and CFO Kristian Borbos on 7 November at 12.00 AM when they present the Q3 report 2024. Focus will be on Q3 report and the underlying growth in the CRO business area. Besides that, we expect an update on potential triggers in the D&P pipeline.

Today, Gubra reported its Q3 2024 results. The company saw another strong quarter in the CRO business, driven by obesity service which is a major topic for the biotech and pharma industry.Read more here.

Boehringer Ingelheim, Gubra's partner in multiple obesity projects, has decided to discontinue the clinical obesity project NYP2.

We have revised our DCF-model, guided by the company, to reflect new estimates for the total obesity market in 2030. With the current share price in line with our latest one-pager from June 2024, the model indicates a lower probability og success (PoS) in the base case.

Meet and ask questions to Gubra’s management – CEO Henrik Blou and CFO Kristian Borbos on 23 August at 13.00 when they present the Q2 report 2024.